Lion Biotechnologies to Present at the BioCentury Future Leaders Conference
March 21 2014 - 8:00AM
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company
focused on the development and commercialization of novel cancer
immunotherapies based on tumor-infiltrating lymphocytes (TILs),
today announced that Chief Executive Officer Manish Singh, Ph.D.,
will be presenting at the BioCentury Future Leaders in the Biotech
Industry Conference at the Millennium Broadway Hotel in New York
City. The presentation is scheduled for Friday, March 28, 2014, at
2:30 pm Eastern Time.
A webcast of Dr. Singh's presentation will be available both
live and on replay. The presentation will be available via webcast
at https://www.webcaster4.com/Webcast/Page/392/3641. A replay will
also be available for 90 days following the live presentation. The
live webcast and subsequent archived replay of Lion
Biotechnologies' presentation will also be accessible via the
Investors section of the Company's web site at
http://lbio.com/investors/ under "Recent Events."
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of
T-cells and engineered T-cells for the treatment of various
cancers. The company's lead product candidate is a ready-to-infuse
autologous T-cell therapy utilizing tumor-infiltrating lymphocytes
(TILs) for the treatment of patients with Stage IV metastatic
melanoma, and is based on a clinical CRADA with the National Cancer
Institute along with physician-sponsored investigational therapy at
the MD Anderson Cancer Center and the H. Lee Moffitt Cancer &
Research Institute. For more information, please visit
http://www.lionbio.com.
CONTACT: Investor Relations
The Trout Group
Gitanjali Jain Ogawa
646-378-2949
gogawa@troutgroup.com